PubMed · 1987 · 19 citations · 0 references
MedicinePharmacologyPharmacotherapyAutoimmunityImmunotherapyRheumatologyAutoimmune DiseasesAutoimmune Rheumatic DiseasesInflammatory ArthritisJoint DiseaseRheumatoid ArthritisD-penicillamine TherapyDisease Activity MeasurementPilot Study DesignPilot Study Sample SizeRefractory Rheumatoid ArthritisRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis Therapy
In a 6-month open pilot study 25 patients with Rheumatoid Arthritis (RA) whose disease was refractory to Gold or D-Penicillamine (DPA) were given Sulphasalazine (SAS) in addition. Three patients withdrew because of nausea. Twenty-two patients who completed therapy showed significant improvement in clinical and laboratory measures of disease activity.